NEUROLOGICAL AND PSYCHIATRIC ADVERSE-EFFECTS OF IMMUNOLOGICAL THERAPY

被引:60
作者
MEYERS, CA
VALENTINE, AD
机构
[1] Department of Neuro-Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, 77030, 1515 Holcombe Blvd
关键词
D O I
10.2165/00023210-199503010-00006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Immunological therapy with cytokines can cause acute, subacute, delayed and, occasionally, irreversible toxicity to the CNS. Neurotoxic adverse effects are manifested by changes in cognitive, motor and emotional functioning. Although these changes are sometimes global in nature, most subacute neurotoxic symptoms attributable to interferon-a, interleukin-2 and tumour necrosis factor are specific to frontal-subcortical dysfunction and involve specific neuroanatomical and neurochemical systems. The symptoms observed typically include memory deficits, difficulties with motivation and flexible thinking (frontal lobe executive function) and motor coordination. Reasoning, language functions and visual perception are generally not affected. Depression and other psychiatric presentations are common and appear to be due to the biochemical changes induced by cytokines rather than psychological reactions to the illness for which the agents are administered. The mechanism of action of cytokines on brain function may include alterations in neurotransmitter function (mostly involving opioid and dopaminergic systems), induction of the release of neuroendocrine hormones and of other cytokines. Improved understanding of the mechanism of cytokine action in the brain is guiding the development of treatment interventions to reduce or eliminate CNS toxicity without sacrificing therapeutic efficacy. In addition, studies of cytokine neurotoxicity have advanced our knowledge of the normal role of these agents in the CNS.
引用
收藏
页码:56 / 68
页数:13
相关论文
共 123 条
[1]   COMBINATION OF INTERFERON AND PREDNISONE IN HUMAN CANCER [J].
ABDI, EA .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (04) :723-724
[2]   NEUROPSYCHIATRIC MANIFESTATIONS OF HUMAN-LEUKOCYTE INTERFERON THERAPY IN PATIENTS WITH CANCER [J].
ADAMS, F ;
QUESADA, JR ;
GUTTERMAN, JU .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (07) :938-941
[3]  
ADAMS F, 1988, J NEURO-ONCOL, V6, P355
[4]   INTERFERONS AS MACROPHAGE-ACTIVATING FACTORS .2. ENHANCED SECRETION OF INTERLEUKIN-1 BY LIPOPOLYSACCHARIDE-STIMULATED HUMAN-MONOCYTES [J].
ARENZANASEISDEDOS, F ;
VIRELIZIER, JL .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1983, 13 (06) :437-440
[5]  
AUERBACH V, 1989, J CLIN EXP NEUROPSYC, V11, P75
[6]   EFFERENT CONNECTIONS OF THE LATERAL HYPOTHALAMIC AREA OF THE RAT - AN AUTORADIOGRAPHIC INVESTIGATION [J].
BERK, ML ;
FINKELSTEIN, JA .
BRAIN RESEARCH BULLETIN, 1982, 8 (05) :511-526
[7]   TRANSIENT FOCAL NEUROLOGIC DEFICITS COMPLICATING INTERLEUKIN-2 THERAPY [J].
BERNARD, JT ;
AMERISO, S ;
KEMPF, RA ;
ROSEN, P ;
MITCHELL, MS ;
FISHER, M .
NEUROLOGY, 1990, 40 (01) :154-155
[8]   INTERLEUKIN-2 MODIFIES THE BIOELECTRIC ACTIVITY OF SOME NEUROSECRETORY NUCLEI IN THE RAT HYPOTHALAMUS [J].
BINDONI, M ;
PERCIAVALLE, V ;
BERRETTA, S ;
BELLUARDO, N ;
DIAMANTSTEIN, T .
BRAIN RESEARCH, 1988, 462 (01) :10-14
[9]   ALPHA-INTERFERON MODIFIES CORTICAL EEG ACTIVITY - DOSE-DEPENDENCE AND ANTAGONISM BY NALOXONE [J].
BIRMANNS, B ;
SAPHIER, D ;
ABRAMSKY, O .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1990, 100 (1-2) :22-26
[10]   COMMON PATHWAYS OF INTERFERON AND HORMONAL ACTION [J].
BLALOCK, JE ;
STANTON, JD .
NATURE, 1980, 283 (5745) :406-408